Turning Merck's COPD drug against resistant prostate cancer

Aggressive castration-resistant prostate cancer can persist after treatment with standard-of-care hormone therapies targeting the androgen receptor. Now a team led by Duke University scientists has identified a cell surface receptor that drives this resistance, and a Merck drug that inhibits prostate tumor growth in mice.